about
Complications associated with drug and nutrient interactions.Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee.International consensus guidelines for nutrition therapy in pancreatitis.A parenteral nutrition use survey with gap analysis.Improvement of medication event interventions through use of an electronic database.Perspectives on parenteral micronutrient shortages.Parenteral nutrition: can outcomes be improved?Compliance with safe practices for preparing parenteral nutrition formulations.ASPEN statement on parenteral nutrition standardization.A key to the literature of total parenteral nutrition.Nutritional support of the critically ill patient.Femoral catheters increase risk of infection in total parenteral nutrition patients.Recent advances: parenteral nutrition support.Heparin does not reduce catheter sepsis during total parenteral nutrition.Parenteral nutrition: short term effects on hepatic clearance of sodium taurocholate and indocyanine green.Proceedings From FDA/A.S.P.E.N. Public Workshop: Clinical Trial Design for Intravenous Fat Emulsion Products, October 29, 2013.Parenteral nutrition utilization: response to drug shortages.A "call to action" for an expanded pharmacist role in influencing the quality of nutrition care.Hyperglycemic events in non-intensive care unit patients receiving parenteral nutrition.Introduction and goals of the A.S.P.E.N. parenteral nutrition safety summit.Implementation of a "second victim" program in a pediatric hospital.Hyperglycemia associated with high, continuous infusion rates of total parenteral nutrition dextrose.Effect of nutritional status on organic anion clearance by the swine liver.Hyperosmolar, hyperglycemic, nonketotic coma in a patient receiving home total parenteral nutrient therapy.Compatibility of medications with 3-in-1 parenteral nutrition admixtures.Advancement of nutrition support in clinical pharmacy.Growth of bacteria and fungi in total nutrient admixtures.Excretion of meperidineOutcomes of cancer and noncancer patients on HPNQuality assurance for a nutritional support serviceParenteral nutrition for marrow transplant recipients: evaluation of an increased nitrogen dosePostgraduate academic desires: senior doctor of pharmacy studentsPharmacists' opinions about and compliance with recommendations for intravenous admixture practicesConcurrent quality assurance for a nutrition-support serviceConsiderations in establishing fees for home-care pharmaceutical servicesProviding 24-hour nutrient infusions to critically ill patientsA key to the literature of total parenteral nutrition: update 1987Hemoglobin A1C in home parenteral nutritionEvaluation of nitrogen utilization in patients receiving total parenteral nutritionEffect of nitrogen intake on urea appearance in patients receiving total parenteral nutrition and hemodialysis
P50
Q35634393-5FAB39DA-E46C-470F-9AFE-422671AB6586Q37673429-0B079807-9119-499A-89E4-77EAC103F235Q37998013-55324118-3EF0-4D03-BE61-1481CDFEAAD3Q38056703-786EDBF6-15D3-4667-9A3E-C07742A3DD87Q38139273-E1961FF5-2420-4C3D-B0C8-280801702BBFQ38292547-7C9DA91D-F9AB-49CF-BF44-0EDD9B0BE5A2Q39506430-82DB8521-3B3C-40FE-A222-10DD1DC402DAQ39594900-3A3F2ECD-461B-49FF-AABC-9BE42A439819Q40181502-42EAB6BC-7EB8-4B19-BA88-871F6F7270FCQ40206946-942627DC-EF45-4296-9299-B9F628862ACDQ40208058-35258BEF-A70F-4524-B9DD-D57546ECB7E0Q40514119-C9749A0D-E74C-4D5C-9C60-D9E65BA28905Q40529614-C0F635C5-AE84-4150-ADD0-3AFA855F03F2Q40818389-1A29B3EF-053A-4790-881F-0EB2885FA1DDQ41343911-8F68375B-DBE5-415F-8154-F76FD77B7FA9Q41726855-CE52EF72-42B3-4B81-8742-99B517A99BB9Q44116759-9F9BF975-C30B-4D74-8F14-D4874D8E2FA7Q45909546-6535520A-D73A-4E5A-A301-32CE04139D62Q45947315-E5E2E882-2F5D-4BAB-9533-BC96A1477768Q48011895-749B704A-1723-4A74-9691-7DCF95CA7C1DQ50946921-51A76C48-18A4-42C8-A4F4-F1699AC0DEB5Q50967741-3F08732E-887B-4590-8202-7AB218D4396DQ51606821-054E0E34-2AF3-495A-B083-94AF609F06A5Q52076762-A7FEB355-F435-4DA1-BDF9-38E3B205D438Q52534270-E03628BF-9DDD-4828-B941-B01A3789552EQ54150179-5A85EBAE-9DD6-4439-BC1A-80CD38A8E535Q54787675-27837AFD-7BBC-4526-9AA8-166257B7C727Q67266441-1D8C7A09-9D6B-408D-BFCD-4E8AE587F7D1Q67287759-B9DD4ADB-1B56-4F49-8246-E585F8E95CD3Q67829282-DEBF518B-B48F-4D48-99D7-2A130C81BD99Q67990511-C372FFE0-3224-453B-BEE4-9D2658DC2DD3Q68434058-2C8A394E-4CF1-4568-A479-0A8AB7B119D2Q68777420-67106272-928F-4066-9350-3DBEFCA0CACBQ69261660-5F94E94F-290E-4D89-8883-EF375D90050AQ69533983-33A93499-3ED7-4CE8-801E-CF4DBC0329E5Q70307720-9E2E218E-575C-4C5D-B21A-8FE1FFA3C98AQ70348851-0BD612C4-CEDA-4DA7-B7D9-0045FB3EF168Q70428764-D1F2D612-D508-47B9-B6D6-7C81C163D8CCQ70434867-66E7A1AB-3B7F-4576-80E1-DB658B3BF690Q70489067-CC901562-FFE1-421C-B5FC-6A017039A473
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jay M Mirtallo
@ast
Jay M Mirtallo
@en
Jay M Mirtallo
@es
Jay M Mirtallo
@nl
Jay M Mirtallo
@sl
type
label
Jay M Mirtallo
@ast
Jay M Mirtallo
@en
Jay M Mirtallo
@es
Jay M Mirtallo
@nl
Jay M Mirtallo
@sl
prefLabel
Jay M Mirtallo
@ast
Jay M Mirtallo
@en
Jay M Mirtallo
@es
Jay M Mirtallo
@nl
Jay M Mirtallo
@sl
P106
P21
P31
P496
0000-0003-0736-6171
P569
2000-01-01T00:00:00Z